Tom van Meerten
dr.
I am a hematologist involved in patient care, clinical and translation research in the field of malignant lymphoma. I focus on translational medicine on diffuse large B cell lymphoma and mantle cell lymphoma. My question by all our findings: how does the patient profit or does it help me to treat the patients. The focus of my research group is on DNA repair, cell cycle and cell death. We test novel combinations of existing anti-cancer agents to ultimately improve the treatment of patients suffering from lymphoma. I participate in the organization of new clinical trials both international (European Mantle cell Lymphoma Network) and national (HOVON). Moreover, I am actively involved in clinical trials concerning the application of CAR T cells for patient with lymphoma.
Whole-body CD8+ T-cell PET imaging in patients with large B-cell lymphoma before and during CD19-directed CAR T-cell therapy: a phase 2 study.
Published in: Nature Communications
Access to document
10.1038/s41467-025-66767-9
document
Chimeric antigen receptor T-cell therapy (CART) has revolutionized the treatment of patients with refractory/relapsed large B-cell lymphoma (R/R LBCL). Limited biopsy data indicate that a higher activated CD8 + T-cell density is associated with tumor response. However, tumor biopsies fail to capture the systemic kinetics of CD8 + T-cells. Therefore, we conducted an exploratory phase 2 single-arm trial utilizing a zirconium-89-labeled one-armed anti-CD8α antibody ( 89ZED88082A) to enable whole-body imaging of CD8 + T-cells through positron emission tomography (PET) (NL9034; EUCTR2020-004749-35-NL). Imaging analysis was performed in 23 patients...
Janneke W de Boer, Kylie Keijzer, Jaap A van Doesum, Nienke A M Smit, Adrienne H Brouwers, Joyce van Sluis, Marjolijn N Lub-de Hooge, Frank R Pierik, Gerwin A Huls, Lisanne V van Dijk, Lydia Visser, Arjan Diepstra, Walter Noordzij, Simon P Williams, Alexander Ungewickell, Sjoerd G Elias, Elisabeth G E de Vries, Anne G H Niezink, Tom van Meerten
Population-based validation of the CAR-HEMATOTOX for hematotoxicity, infections and survival after CART in R/R LBCL
Published in: Blood Advances
Access to document
10.1182/bloodadvances.2025016689
document
Early identification of patients at risk for immune effector cell-associated hematotoxicity (ICAHT) is essential to minimize non-relapse mortality. The CAR-HEMATOTOX (HT) score is an implemented risk-stratification tool for ICAHT, infections and survival in relapsed/refractory large B-cell lymphoma (R/R LBCL) patients receiving CAR T-cell therapy (CART). Although validated in its defining study, the HT score was developed in a small cohort, necessitating independent external validation. This study externally validates the HT score in a real-world population-based cohort of adults with R/R LBCL receiving CART. The HT score, based on...
Janneke W de Boer, Kylie Keijzer, Suzanne van Dorp, Pim G N J Mutsaers, Anne GH Niezink, Jaap A van Doesum, Yasmina Im Serroukh, Louise W Muntendam, Astrid E Pulles, Esther J Kret, Aniko Sijs-Szabo, Jesse Oomen, Astrid Mp Demandt, Wendy Bc Stevens, Maria T Kuipers, Elise Ra Pennings, Anne Mea Spanjaart, Marie José Kersten, Margot Jak, Lisanne Vania van DijkMarjolein Wm van der Poel, Joost Sp Vermaat, Tom van van Meerten
Transformed FL shows improved survival after CAR T-cell therapy compared to de novo LBCL, but early transformation (<12 months) defines a poor-risk subgroup: Results from a nationwide cohort
Published in: Blood
Access to document
10.1182/blood-2025-959
Hilde Van Der Galien, Pim Mutsaers, Margot Jak, Marjolein Van Der Poel, Marije Nijk, Kees Meijer, Marieke Tienstra, Kylie Keijzer, Janneke De Boer, Astrid Demandt, Amaria Vledder, Anne Spanjaart, Elise Pennings, Maria Kuipers, Marie José Kersten, Jaap Van Doesum, Anne Niezink, Joost Vermaat, Suzanne Van Dorp, Tom Van Meerten
Higher helios⁺ treg levels pre- and post-CAR T infusion are associated with inferior outcomes in patients with LBCL
Published in: Blood
Access to document
10.1182/blood-2025-1779
Hilde Van Der Galien, Nienke Smit, Marije Nijk, Marieke Tienstra, Thies Moolenaar, Janneke De Boer, Kylie Keijzer, Jaap Van Doesum, Anne Niezink, Gerwin A. Huls, Kees Meijer, Tom Van Meerten
T-cell and antibody responses in immunocompromised patients with hematologic malignancies indicate strong potential of SARS-CoV-2 mRNA vaccines
Published in: Haematologica
Access to document
10.3324/haematol.2024.287136
document
Cilia R. Pothast, Quincy Hofsink, Sabine Haggenburg, Romy C. Dijkland, Marian Van de Meent, Kayleigh Van Dijk, Michel S. Bhoekhan, Nienke J.E. Haverkate, Johan Van Meerloo, J. H.Frederik Falkenburg, Ruben A.L. De Groen, Annoek E.C. Broers, Jaap A. Van Doesum, Rob S. Van Binnendijk, Gerco Den Hartog, Birgit I. Lissenberg-Witte, Arnon P. Kater, Gaby P. Smits, Dorine Wouters, Ester M.M. Van LeeuwenHetty J. Bontkes, Neeltje A. Kootstra, Sandra Vogels-Nooijen, Debbie Van Baarle, Rory D. De Vries, Tom Van Meerten, Pim G.N.J. Mutsaers, Abraham Goorhuis, Inger S. Nijhof, Mette D. Hazenberg, Mirjam H.M. Heemskerk, Caroline E. Rutten, Cobra Kai Study Team